Dabigatran

Dabigatran: A Review of Clinical and Pharmacoeconomic Evidence

Created by Partners HealthCare’s Center for Drug Policy and Pharmacy Cost Management Committee, the article, provided by Lippincott Williams & Wilkins, addresses dabigatran. Dabigatran etexilate is a commercially available oral direct thrombin inhibitor. This article covers its clinical evidence along with pharmacoeconomic evidence. The full article is available as a PDF, requiring Adobe Reader.

This guideline may be available to you through your medical library access. If no access is available, there may be a subscription fee through the provider website.